Health Centers in West Gojjam and South Gondar zones
Bahir Dar, Amhara, Ethiopia
NCT Number: NCT06296238
The goal of this observational child follow-up study is to examine the effects of prenatal nutrition and infection management interventions on long-term child neurodevelopment.
Participants are the offspring of mothers in the main study entitled "Enhancing Nutrition and Antenatal Infection Treatment (ENAT)" that was conducted in the rural Amhara region of Ethiopia. In the ENAT pragmatic clinical effectiveness study, 2399 pregnant women were randomized to receive routine prenatal care, a package of enhanced nutrition interventions (balanced energy protein supplement, iodized salt, iron-folic acid and counseling), a package of enhanced infection management interventions (genitourinary tract infection screening-treatment, deworming), or a combination of both packages. The impact of these antenatal nutrition and infection interventions on birth outcomes (infant birth size and gestational length) was examined in the main study. In this longitudinal cohort study, we will follow the offspring from the ENAT pregnancy cohort up to 24 months postnatal age and assess their growth, health and neurodevelopment.
The main questions it aims to answer are:
1. What are the effects of pregnancy interventions from the parent study (ENAT) on offspring neurodevelopmental outcomes? 2. What are the associations between maternal-newborn iron status and inflammation on infant neurodevelopment? 3. What are the associations between maternal iodine status and thyroid function on infant neurodevelopment?
We will follow children of mothers from the parent ENAT study to monitor their growth, health, and neurodevelopment up to 24 months postnatal age.
Looking for future studies?
Notify Me9 month–27 month
All sexes
Observational
Bahir Dar, Amhara, Ethiopia
In low-resource settings, undernutrition and infections during the first 1000 days of life are prevalent, modifiable risk factors that may have lifelong effects on a child's cognitive and psychological development, yet effective interventions addressing prevailing mechanisms are still to be validated. Iron, protein and energy are critical nutrients that support the rapidly developing fetal brain, however, among women of reproductive age in Sub-Saharan Africa, 10% are underweight and 20% have iron deficiency anemia. Pregnancy infections are also common in Africa, where one in three women have a geo-helminthic infection resulting in blood loss, iron deficiency and inflammation. The interaction between iron and inflammation in pregnancy is particularly complex. NICHD has identified the complex relationship between nutrition, inflammation, and neurodevelopment as a major research gap. A barrier to progress is that mechanistic understanding of prenatal brain development is based on animal or observational studies. We present a unique opportunity to leverage an ongoing randomized controlled trial (RCT) to examine the consequences of pregnancy nutrition and inflammation on child neurodevelopment.
The Enhancing Nutrition and Antenatal Infection Treatment (ENAT) RCT enrolled pregnant women in Amhara, Ethiopia to study independent and overlapping effects of prenatal nutrition and infection interventions on birth outcomes. Women were randomized to receive: 1) standard prenatal care, 2) enhanced nutrition package (ENP) (counseling, iron-folic acid [IFA], iodized salt, and balanced energy protein [BEP] supplementation), 3) enhanced infection management package (EIMP) (anti-helminthics, urinary tract infection treatment), or 4) ENP+EIMP. The current follow-up study (Longitudinal Infant Development and Growth; LIDG) will investigate biological pathways by which ENAT interventions, specifically iron, protein-energy, and inflammation, influence child neurodevelopment.
Our overarching hypotheses are that improving prenatal nutrition will improve brain structural and network development, reducing inflammation will improve white matter maturation, and the combination will have synergistic effects on child neuro-cognitive outcomes. This study will follow up to 500 ENAT children to assess neurodevelopment through 24 months of age, including neurobehavior and neural networks.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 24 months
Measured by absolute power of alpha frequency band on mobile electroencephalography
Time frame: 24 months
Absolute power of theta band (3-5 Hz) as measured on mobile EEG
Time frame: 24 months
VEP P1 peak latency (ms)
Time frame: 12 months
Measured with infant eye tracking during Cecile Attention Task
Time frame: 12 months
Multisensory Attention Assessment Protocol
Time frame: 12 months
Hammersmith Infant Neurological Exam (HINE) Total Score
Time frame: 24 months
Bayley-III Cognitive Scale
Time frame: 24 months
Length for age Z score [standard deviations from the median for age and sex, range: -5 (worse) to +5 (better)]
Time frame: 24 months
Weight for age z score [standard deviations from the median for age and sex, range: -5 (worse) to +5 (better)]
Time frame: 24 months
Head circumference for age z score [standard deviations from the median for age and sex, range: -5 (worse) to +5 (better)]
Time frame: 24 months
Body mass index
Time frame: 12 months
Total brain volume (cm3); regional volumes measure by hyperfine low field MRI
Time frame: 12 and 24 months
Fever, diarrhea, hospitalization
Time frame: 24 months
Relative power of alpha, theta, beta, gamma bands
Time frame: 24 months
Neural network efficiency and organization across brain regions measured on EEG
Brown University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00168714
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Wilmington, North Carolina, United States
View Trial DetailsNCT00001106
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Los Angeles, California, United States
View Trial DetailsNCT00000960
AIDS-Related Complex, Blood-Borne Infections
Birmingham, Alabama, United States
View Trial DetailsNCT05951452
Developmental Origins of Health and Disease, Endometriosis
Montpellier, France
View Trial Details